Bunashimeji

Metadata

Regulatory Status

Japan

• Food status: One of the most popular cultivated mushrooms in Japan, widely consumed as a daily food ingredient. Japan is the largest producer of Bunashimeji.
• Pharmaceutical status: Not listed in the Japanese Pharmacopoeia. Available as a food product; not registered as a pharmaceutical.
• Commercial cultivation: Large-scale industrial cultivation in Japan using bottle cultivation methods; annual production exceeds 100,000 metric tons.

United States

• Food status: Increasingly available in American supermarkets and Asian grocery stores as “beech mushroom” or “shimeji.”
• Dietary supplement: Available in some supplement formulations, typically as part of mushroom blends rather than as a standalone product.
• No GRAS determination for concentrated extracts, though the whole mushroom has a long history of safe food consumption.

European Union

• Food status: The fruiting body has growing commercial availability in European markets. Its history of consumption within the EU may not predate the 1997 novel food threshold, and status may vary by member state.
• Mycelium extracts: Concentrated extracts would likely require novel food authorization.

China and Korea

• China: Increasingly cultivated for both domestic consumption and export. Not listed in the Chinese Pharmacopoeia.
• Korea: Commercially cultivated and widely consumed. Known in Korean as “Neutari beoseot” (though this name is sometimes applied to other Hypsizygus/Pleurotus species).

Conditions & Indications

Primary: Immune Modulation (Preclinical Evidence)

• Beta-glucan immunostimulation: Water-soluble polysaccharides from H. marmoreus exhibit strong immunomodulatory activity in vitro. Four proteoglycans sequentially extracted from the mushroom (containing 19.8—82.4% carbohydrates and 7.7—67.3% protein) demonstrated dose-dependent immune cell activation. High molecular weight glucans (500—2,000 kDa) were more effective than lower molecular weight fractions.
• Cytokine modulation: Polysaccharide fractions stimulate production of TNF-alpha, IFN-gamma, and IL-2, key cytokines in anti-tumor immune surveillance and pathogen defense.
• Intestinal immune activation: Studies on mucosal immune cells demonstrate that Bunashimeji extracts activate intestinal lamina propria leukocytes, suggesting immunomodulatory effects at the gut mucosal interface — the body’s largest immune surface.

Secondary: Anti-Tumor Activity (Preclinical Evidence)

• Ribosome-inactivating proteins: Hypsin and marmorin are the most pharmacologically distinctive bioactives in Bunashimeji. Hypsin (20 kDa) demonstrates antiproliferative activity against mouse leukemia cells and human leukemia and hepatoma cells, with potent translation inhibition (IC50 = 7 nM). Marmorin (9.5 kDa) inhibits proliferation of hepatoma HepG2 cells (IC50 = 0.15 microM), breast cancer MCF-7 cells (IC50 = 5 microM), and HIV-1 reverse transcriptase activity (IC50 = 30 microM).
• Cell adhesion and metastasis: A 41 kDa protein isolated from H. marmoreus demonstrates adhesion activity for animal tumor cells via type IV collagen interaction, with potential relevance to metastasis mechanisms.
• Polysaccharide anti-tumor effects: Beta-glucan fractions promote immune-mediated tumor suppression through enhanced NK cell cytotoxicity and macrophage activation, consistent with the polysaccharide-driven anti-tumor mechanisms observed across medicinal mushrooms.

Secondary: Cardiovascular and Metabolic Health (Preclinical Evidence)

• Anti-atherosclerotic effect: In the comparative Mori et al. (2008) study, dietary supplementation with 3% H. marmoreus powder in ApoE-deficient mice for 10 weeks significantly reduced serum total cholesterol at multiple time points and decreased atherosclerotic lesion area. Notably, Bunashimeji showed the strongest anti-atherosclerotic effect among the three mushrooms tested (alongside Pleurotus eryngii and Grifola frondosa).
• ACE inhibition: Oligopeptides from H. marmoreus have demonstrated angiotensin I-converting enzyme (ACE) inhibitory activity, suggesting potential for blood pressure modulation.
• Cholesterol lowering: The naturally occurring lovastatin content contributes to HMG-CoA reductase inhibition, complementing the polysaccharide-mediated cholesterol reduction mechanisms.

Emerging/Preclinical

• Anti-diabetic potential: Extracts show signs of controlling obesity and insulin dependence in experimental mouse models, though specific mechanisms and dose-response relationships have not been fully characterized.
• Lung protection: Polysaccharides extracted from Bunashimeji reduced biochemical and structural indicators of lung injury in experimental mice, suggesting potential respiratory protective applications.
• Neuroprotective and procognitive effects: Indole compounds and other bioactive substances in H. marmoreus play a role in the prevention of depression and demonstrate procognitive activities in preclinical models. This aligns with the mushroom’s ergothioneine content and antioxidant profile.
• Antimicrobial activity: Extracts of H. tessellatus inhibit the growth of E. coli, Serratia marcescens, Staphylococcus aureus, and Bacillus subtilis in vitro.
• Anti-HIV activity: Marmorin demonstrates HIV-1 reverse transcriptase inhibitory activity (IC50 = 30 microM), though this is an in vitro observation with no in vivo validation.

Mechanism of Action

Primary Mechanisms

1. Ribosome-inactivating protein (RIP) anti-tumor activity: Hypsin and marmorin belong to the ribosome-inactivating protein family — enzymes that inactivate ribosomes by catalytically removing adenosine residues from ribosomal RNA (RNA N-glycosidase activity). This irreversibly blocks protein synthesis in target cells. In tumor cells, this translation inhibition triggers apoptosis. Hypsin is notable for its thermostability (unusually heat-resistant for a protein) and dual antifungal-antiproliferative activity. Marmorin demonstrates broader activity including HIV-1 reverse transcriptase inhibition, suggesting interaction with nucleic acid processing beyond ribosomal targets. The presence of two distinct ribosome-inactivating proteins in a single edible mushroom species is pharmacologically unusual.

2. Beta-glucan pattern recognition and immune activation: Water-soluble beta-(1,3)-glucans from H. marmoreus are recognized by innate immune receptors, primarily dectin-1 and complement receptor 3 (CR3), on macrophages, dendritic cells, and neutrophils. Receptor engagement activates Syk kinase, NF-kB, and MAPK signaling cascades, leading to enhanced phagocytosis, respiratory burst, and cytokine production (TNF-alpha, IFN-gamma, IL-2, IL-12). Higher molecular weight glucan fractions (500—2,000 kDa) are more immunologically active, likely due to greater receptor cross-linking capacity. The proteoglycan fractions (protein-polysaccharide complexes) may have enhanced bioactivity compared to pure polysaccharides, similar to the proteoglycan mechanism described for Huaier.

3. Multi-compound lipid metabolism modulation: The anti-atherosclerotic effect demonstrated in ApoE-deficient mice likely results from the combined action of: (a) lovastatin-mediated HMG-CoA reductase inhibition; (b) beta-glucan bile acid binding and cholesterol excretion; (c) antioxidant protection of LDL from oxidation (via ergothioneine and phenolic compounds); and (d) ACE-inhibitory oligopeptides contributing to vascular health. This multi-target mechanism may explain why Bunashimeji showed superior anti-atherosclerotic effects compared to the other mushrooms in the Mori et al. comparative study.

Secondary Mechanisms

• ACE inhibition: Specific oligopeptides from H. marmoreus inhibit angiotensin I-converting enzyme, the same target as pharmaceutical ACE inhibitors (captopril, enalapril). By blocking the conversion of angiotensin I to the potent vasoconstrictor angiotensin II, these peptides may contribute to blood pressure reduction.
• Hypsiziprenol terpenoid activity: Hypsiziprenol is a terpenoid compound with reported anti-tumor properties. The genomic characterization of terpenoid biosynthetic pathways in H. marmoreus has revealed the molecular basis for production of these bioactives, opening possibilities for enhanced production through cultivation optimization.
• Glycoprotein HM-3A: This immunomodulatory glycoprotein activates macrophages and enhances cytokine production through pathways that may be partially independent of beta-glucan receptor signaling.
• Ergothioneine cytoprotection: As with other cultivated mushrooms, H. marmoreus contains ergothioneine, which provides intracellular antioxidant protection via OCTN1 transporter-mediated uptake. The mushroom’s ergothioneine content contributes to its overall antioxidant and neuroprotective profile.

Clinical Evidence Summary

Despite its popularity as a culinary mushroom in Japan and growing global market presence, Hypsizygus tessellatus has no published human clinical trials for any therapeutic indication. All pharmacological evidence derives from in vitro studies, animal models, and biochemical characterization of isolated compounds.

Key Preclinical Studies

Evidence Limitations

• No human clinical trials: This is the most significant limitation. No randomized controlled trials, cohort studies, or even case reports of therapeutic use in humans have been published.
• Preclinical translation uncertainty: The ribosome-inactivating proteins hypsin and marmorin demonstrate potent activity in vitro, but their oral bioavailability, in vivo pharmacokinetics, and safety in humans are entirely unknown. Ribosome-inactivating proteins are generally poorly absorbed intact from the GI tract, raising questions about whether food-level consumption delivers therapeutically relevant concentrations.
• Cooking effects on bioactive proteins: Hypsin is notably thermostable, but the effects of standard cooking methods (boiling, stir-frying) on marmorin and other bioactive proteins have not been systematically characterized.
• Limited animal studies: The Mori et al. (2008) anti-atherosclerotic study is the most rigorous animal trial, but it has not been replicated. The diabetic and lung-protective animal studies are preliminary.
• Species confusion in marketplace: Commercial “shimeji” products may include other species (Pleurotus ostreatus or Lyophyllum shimeji), creating confusion in both the marketplace and the research literature.
• Beta-glucan non-specificity: The beta-glucan immunomodulatory evidence, while consistent, is not unique to this species. The specific contribution of H. marmoreus beta-glucans versus those from other medicinal mushrooms has not been adequately differentiated in comparative studies.

Safety Profile

General Assessment

Hypsizygus tessellatus has a long history of safe food consumption in Japan and increasingly worldwide. It is one of the most commercially important cultivated mushrooms in East Asia, consumed daily by millions. No adverse effects have been documented from dietary consumption. The absence of clinical studies means that formal safety evaluation of concentrated extracts or supplements is lacking.

Contraindications

• Mushroom allergy: Individuals with known allergies to shimeji or related basidiomycete mushrooms should avoid consumption. Cross-reactivity with other mushroom species is possible.

Drug Interactions

• No documented drug interactions at food-level consumption.
• Theoretical interactions: The presence of lovastatin (in small amounts) suggests caution with concentrated extracts in patients on statin therapy. ACE-inhibitory peptides could theoretically interact with pharmaceutical ACE inhibitors or ARBs, though this is speculative at food-level consumption.

Side Effects

• Common: No adverse effects reported at normal dietary intake.
• Uncommon: Mild gastrointestinal symptoms possible with very high intake in unaccustomed individuals.
• Note: Raw Bunashimeji mushrooms have a bitter taste and are always cooked before consumption. Cooking eliminates the bitterness and is the traditional preparation method.

Toxicology

• Ribosome-inactivating proteins: While hypsin and marmorin are potent toxins at the cellular level, their oral bioavailability as intact proteins from cooked mushroom consumption is expected to be very low due to gastric acid and protease degradation. No toxicity from dietary consumption has been reported.
• General: No documented toxicity concerns from food-level consumption. As with all cultivated mushrooms, quality of cultivation substrate affects mineral content.

Clinical Dosage

Dietary Consumption (Food Level)

• Japanese culinary intake: Typically consumed as 100—150 g fresh mushroom clusters per serving, several times per week
• Preparation: Always cooked (sauteed, simmered, stir-fried, or added to soups). Raw consumption is not traditional due to bitter taste.
• Both varieties: White (Bunapi-shimeji) and brown varieties are nutritionally comparable, though some studies suggest minor differences in bioactive concentrations

Dried Mushroom Powder

• No clinically validated dose. Products on the market suggest 1—5 g/day as part of mushroom blend supplements
• Polysaccharide content: Dried H. marmoreus contains significant beta-glucan levels, though standardization is not common in commercial products

Extract Preparations

• No standardized clinical dose has been established
• Hot-water extraction captures polysaccharides and glycoproteins
• Ethanol extraction may capture terpenoids (hypsiziprenol) and lovastatin
• Research preparations: Various concentrations used in preclinical studies cannot be directly translated to human oral dosing

Form Selection Guidance

For general health and immune support, regular dietary consumption of cooked Bunashimeji mushrooms provides the broadest spectrum of bioactives in a food matrix with established safety. The unique ribosome-inactivating proteins (hypsin, marmorin) are primarily of pharmacological research interest rather than practical supplementation targets, given the uncertain oral bioavailability of intact proteins. For polysaccharide-focused immune support, hot-water extracts standardized to beta-glucan content would be the most rational preparation, though clinical dosing data is unavailable.

Sources

• Mori K, Kobayashi C, Tomita T, Inatomi S, Ikeda M. Antiatherosclerotic effect of the edible mushrooms Pleurotus eryngii (Eringi), Grifola frondosa (Maitake), and Hypsizygus marmoreus (Bunashimeji) in apolipoprotein E-deficient mice. Nutr Res. 2008;28(5):335-342
• Lam SK, Ng TB. Hypsin, a novel thermostable ribosome-inactivating protein with antifungal and antiproliferative activities from fruiting bodies of the edible mushroom Hypsizigus marmoreus. Biochem Biophys Res Commun. 2001;285(4):1071-1075
• Wong JH, Wang HX, Ng TB. Marmorin, a new ribosome inactivating protein with antiproliferative and HIV-1 reverse transcriptase inhibitory activities from the mushroom Hypsizigus marmoreus. Appl Microbiol Biotechnol. 2008;81(4):669-674
• Tanaka T, Kawashima H, Kato T, et al. Isolation of a 41-kDa protein with cell adhesion activity for animal tumor cells from the mushroom Hypsizigus marmoreus by affinity chromatography with type IV collagen immobilized on agarose. Biosci Biotechnol Biochem. 2000;64(4):862-865
• Chen J, Lai Y, Wang L, et al. Molecular properties of water-unextractable proteoglycans from Hypsizygus marmoreus and their in vitro immunomodulatory activities. Molecules. 2012;17(1):207-218
• Krakowska A, Reczyński W, Muszyńska B. Hypsizygus marmoreus as a source of indole compounds and other bioactive substances with health-promoting activities. Molecules. 2022;27(24):8917
• Lee HS, Kim IH, Nam TJ. Hypsizygus marmoreus as a source of bioactive substances with health-promoting activities: a review. Int J Med Mushrooms. 2023;25(1):1-15
• Razak MA, et al. Antimicrobial, antioxidant and cytotoxic properties of Hypsizygus tessulatus cultivated in Bangladesh. Res J Med Plant. 2012;6:300-308
• Zhang J, Meng G, Zhang C, et al. Genomic discovery of the hypsin gene and biosynthetic pathways for terpenoids in Hypsizygus marmoreus. BMC Genomics. 2018;19:789
• Ren Z, Guo Z, Meydani SN, Wu D. Immunomodulatory effect of mushrooms on cytotoxic activity and cytokine production of intestinal lamina propria leukocytes does not necessarily depend on beta-glucan contents. Food Chem. 2011;126(4):1642-1649
• Kues U, Liu Y. Fruiting body production in basidiomycetes. Appl Microbiol Biotechnol. 2000;54(2):141-152

Connections

• Japanese culinary-medicinal mushrooms: Bunashimeji belongs to a cluster of Japanese cultivated mushrooms valued for both culinary and health properties, alongside Maitake (Grifola frondosa), Shiitake (Lentinula edodes), and Enokitake (Flammulina velutipes). Among these, Bunashimeji is the least studied medicinally but has a distinctive bioactive profile due to its ribosome-inactivating proteins.
• Comparative anti-atherosclerotic evidence: The Mori et al. (2008) study directly compared Bunashimeji with King Oyster Mushroom (Pleurotus eryngii) and Maitake (Grifola frondosa) in the same atherosclerosis model, finding Bunashimeji had the strongest effect. This comparative evidence is valuable for understanding the relative cardiovascular potential across culinary mushroom species.
• Ribosome-inactivating protein uniqueness: The presence of hypsin and marmorin distinguishes Bunashimeji from most other culinary-medicinal mushrooms. While ribosome-inactivating proteins are found in various plants (ricin from castor beans is the most infamous example), their occurrence in a widely consumed edible mushroom is unusual and warrants further investigation regarding oral bioavailability and safety at concentrated doses.
• Polysaccharide immunomodulation: The beta-glucan immune activation mechanism is shared with virtually all medicinal mushrooms, including Reishi, Turkey Tail, Maitake, and Shiitake. The specific contribution of H. marmoreus proteoglycans (glycoprotein HM-3A) to immune modulation may represent a protein-polysaccharide synergy similar to that observed in Huaier proteoglycan.
• Research opportunity: Among commonly cultivated culinary mushrooms consumed at scale in Japan, Bunashimeji has the largest gap between commercial importance and clinical evidence. Given the promising preclinical profile — particularly the comparative anti-atherosclerotic data and the unique ribosome-inactivating protein pharmacology — human clinical trials would be valuable.